These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 6146164)

  • 1. Low dose bromocriptine: a study of acute effects in chronic mediated schizophrenics.
    Cutler NR; Jeste DV; Kaufmann CA; Karoum F; Schran HF; Wyatt RJ
    Prog Neuropsychopharmacol Biol Psychiatry; 1984; 8(2):277-83. PubMed ID: 6146164
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute and subchronic effects of low-dose bromocriptine in haloperidol-treated schizophrenics.
    Gattaz WF; Rost W; Hübner CK; Bauer K
    Biol Psychiatry; 1989 Feb; 25(3):247-55. PubMed ID: 2643996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bromocriptine in augmentation of antipsychotic response in chronic schizophrenia: a negative pilot report.
    Wells BG; Chu CC; Abi-Darghum A; Saini TS
    Pharmacopsychiatry; 1991 Jul; 24(4):118-20. PubMed ID: 1684441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-dose bromocriptine in neuroleptic-resistant schizophrenia: a pilot study.
    Wolf MA; Diener JM; Lajeunesse C; Shriqui CL
    Biol Psychiatry; 1992 Jun; 31(11):1166-8. PubMed ID: 1356025
    [No Abstract]   [Full Text] [Related]  

  • 5. [Use and value of the therapeutic neuroleptic-bromocriptine combination in schizophrenia].
    Lombertie ER; Durelle G; Fuseau A
    Ann Med Psychol (Paris); 1995 Oct; 153(8):531-4. PubMed ID: 8561400
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group.
    Small JG; Hirsch SR; Arvanitis LA; Miller BG; Link CG
    Arch Gen Psychiatry; 1997 Jun; 54(6):549-57. PubMed ID: 9193196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Placebo-controlled, double-blind study of the effects of proglumide in the treatment of schizophrenia.
    Whiteford HA; Stedman TJ; Welham J; Csernansky JG; Pond SM
    J Clin Psychopharmacol; 1992 Oct; 12(5):337-40. PubMed ID: 1362205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bromocriptine therapy in chronic schizophrenia: effects on symptomatology, sleep patterns, and prolactin response to stimulation.
    Brambilla F; Scarone S; Pugnetti L; Massironi R; Penati G; Nobile P
    Psychiatry Res; 1983 Mar; 8(3):159-69. PubMed ID: 6574535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The behavioral toxicity of bromocriptine in patients with psychiatric illness.
    Perovich RM; Lieberman JA; Fleischhacker WW; Alvir J
    J Clin Psychopharmacol; 1989 Dec; 9(6):417-22. PubMed ID: 2574194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjunctive nadolol in the treatment of acutely aggressive schizophrenic patients.
    Allan ER; Alpert M; Sison CE; Citrome L; Laury G; Berman I
    J Clin Psychiatry; 1996 Oct; 57(10):455-9. PubMed ID: 8909331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Drug treatment of schizophrenic psychoses in puerperium].
    Olbrich HM; Martin P
    Nervenarzt; 1994 Jul; 65(7):482-5. PubMed ID: 7800093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Use of low doses of bromocriptine in chronic schizophrenia resistant to neuroleptics. A preliminary study].
    Wolf MA; Diener JM; Lajeunesse C; Shriqui C
    J Psychiatry Neurosci; 1992 Jun; 17(2):68-71. PubMed ID: 1637801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Comparative efficacy of bromocriptine, carbamazepine and cyproheptadine with neuroleptics in 24 refractory chronic schizophrenic patients].
    Llorca PM; Wolf MA; Lançon C; Bougerol T
    Encephale; 1993; 19(5):565-71. PubMed ID: 8306925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A double-blind trial of carbamazepine in negative symptom schizophrenia.
    Nachshoni T; Levin Y; Levy A; Kritz A; Neumann M
    Biol Psychiatry; 1994 Jan; 35(1):22-6. PubMed ID: 7909450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Naloxone in chronic schizophrenic patients: neuroendocrine and behavioral effects.
    Kleinman JE; Weinberger DR; Rogol A; Shiling DJ; Mendelson WB; Davis GC; Bunney WE; Wyatt RJ
    Psychiatry Res; 1982 Aug; 7(1):1-7. PubMed ID: 6127744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of Ginkgo biloba extract added to haloperidol on peripheral T cell subsets in drug-free schizophrenia: a double-blind, placebo-controlled trial.
    Zhang XY; Zhou DF; Cao LY; Wu GY
    Psychopharmacology (Berl); 2006 Sep; 188(1):12-7. PubMed ID: 16906395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bromocriptine for "negative" schizophrenia.
    Levi-Minzi S; Bermanzohn PC; Siris SG
    Compr Psychiatry; 1991; 32(3):210-6. PubMed ID: 1679383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An open clinical trial of fenfluramine in chronic schizophrenia: a pilot study.
    Kolakowska T; Gadhvi H; Molyneux S
    Int Clin Psychopharmacol; 1987 Jan; 2(1):83-8. PubMed ID: 2889761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group.
    Arvanitis LA; Miller BG
    Biol Psychiatry; 1997 Aug; 42(4):233-46. PubMed ID: 9270900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A study of clinical response to different kinds of neuroleptics in first time medicated schizophrenics.
    Kadota K
    Jpn J Psychiatry Neurol; 1992 Mar; 46(1):127-53. PubMed ID: 1353124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.